Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

The FDA has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until ...

Moderna, Baxter, and Pfizer are our top healthcare picks.

Ex-vaccine regulator Peter Marks promoted "ineffective therapy that gave patients false hope, eroded trust in the regulatory ...

In partnership with NMA and Charles Drew University of Science and Medicine, BDO and The Collective convened some of the ...

Amid a raft of federal changes cutting funding and capacities at the Food and Drug Administration, investors are soon ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...